Programmed Death Ligand 1 (PD-L1) Expression in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
D'Arcangelo, M. [1 ]
Puccetti, M. [2 ]
Bravaccini, S. [3 ]
D'Incecco, A. [4 ]
Ligorio, C. [5 ]
Terracciano, L. [6 ]
Damiani, S. [5 ]
Ravaioli, S. [3 ]
Tumedei, M. M. [3 ]
Bennati, C. [1 ]
Minuti, G. [1 ]
Vecchiarelli, S. [1 ]
Landi, L. [1 ]
Incarbone, M. [7 ]
Milesi, M. [7 ]
Cappuzzo, F. [1 ]
机构：
[1] Ausl Romagna, Oncol Hematol, Ravenna, Italy
[2] Ausl Romagna, Pathol, Ravenna, Italy
[3] IRST, Lab Biosci, Meldola, Italy
[4] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[5] Univ Bologna, Bologna, Italy
[6] Univ Hosp Basel, Basel, Switzerland
[7] Multimedica, Milan, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
NSCLC; Tumor grade; PD-L1;
D O I：
10.1016/j.jtho.2017.09.1937
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PUB074
引用
收藏
页码：S2390 / S2390
页数：1
相关论文
共 50 条
  • [21] Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US
    Kessler, Joshua E.
    Park, Kwon N.
    Grizzle, Amy J.
    Hurwitz, Jason T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (01) : 55 - 61
  • [22] Clinicopathological features of programmed cell death ligand 1 (PD-L1) expression in resected non-small cell lung cancers
    Ohhara, Yoshihito
    Kinoshita, Ichiro
    Tomaru, Utano
    Hatanaka, Kanako C.
    Hatanaka, Yutaka
    Honma, Rio
    Takeuchi, Satoshi
    Shimizu, Yasushi
    Kaga, Kichizo
    Matsuno, Yoshihiro
    Dosaka-Akita, Hirotoshi
    CANCER RESEARCH, 2017, 77
  • [23] Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence
    Lacour, Max
    Hiltbrunner, Stefanie
    Lee, Seok-Yun
    Soltermann, Alex
    Rushing, Elisabeth Jane
    Soldini, Davide
    Weder, Walter
    Curioni-Fontecedro, Alessandra
    CLINICAL LUNG CANCER, 2019, 20 (05) : 391 - 396
  • [24] The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
    Skov, Birgit Guldhammer
    Rorvig, Sara Bird
    Jensen, Thomas Hartvig Lindkaer
    Skov, Torsten
    MODERN PATHOLOGY, 2020, 33 (01) : 109 - 117
  • [25] Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mino-Kenudson, Mari
    CANCER BIOLOGY & MEDICINE, 2016, 13 (02) : 157 - 170
  • [26] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine, 2016, 13 (02) : 157 - 170
  • [27] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine, 2016, (02) : 157 - 170
  • [28] Clinical significance of CD8 and programmed death-ligand 1 (PD-L1) expression in patients with resectable non-small cell lung cancer.
    Kim, Hye Ree
    Song, Haa-Na
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer
    Sepesi, Boris
    Cuentas, Edwin Parra
    Canales, Jaime Rodriguez
    Behrens, Carmen
    Correa, Arlene M.
    Vaporciyan, Ara
    Weissferdt, Annikka
    Kalhor, Neda
    Moran, Cesar
    Swisher, Stephen
    Wistuba, Ignacio
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2017, 29 (03) : 408 - 415
  • [30] Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer
    Lin, Gen
    Fan, Xirong
    Zhu, Weifeng
    Huang, Cheng
    Zhuang, Wu
    Xu, Haipeng
    Lin, Xiandong
    Hu, Dan
    Huang, Yunjian
    Jiang, Kan
    Miao, Qian
    Li, Chao
    ONCOTARGET, 2017, 8 (48) : 83986 - 83994
12345